Skip to main content
The NASS Podcast

The NASS Podcast

By North American Spine Society
The NASS Podcast is a great way to consume education content on-the-go!

The episodes offer in-depth discussions of a variety of topics in spine from key opinion leaders, including: 3D Printing; ACDF vs. Cervical Disc Replacement; Complications; Laminoplasty vs. ACDF; Neuromonitoring During Spine Surgery; Cellular-Based Allografts; Is Surgery for Axial Back Pain Still an Option?; Surgical Management of Degenerative Spondylolisthesis; SpineLine Author Discussions.
Listen on
Where to listen
Apple Podcasts Logo

Apple Podcasts

Breaker Logo

Breaker

Castbox Logo

Castbox

Google Podcasts Logo

Google Podcasts

Overcast Logo

Overcast

Pocket Casts Logo

Pocket Casts

PodBean Logo

PodBean

RadioPublic Logo

RadioPublic

Spotify Logo

Spotify

Stitcher Logo

Stitcher

Effect of Spinal Manipulative and Mobilization Therapies in Young Adults with Low Back Pain
Moderator Erik Westerlund, MD discusses the 2020 JAMA article, "Effect of spinal manipulative and mobilization therapies in young adults with mild to moderate chronic low back pain: a randomized clinical trial" with Literature Review authors Ryan L. McLean, BS and Jonathan N. Grauer, MD. Access the article here. Disclosures: Grauer, Jonathan N.: Board of Directors: LSRS (Nonfinancial, committee/board role); Other: NASS (D). McLean, Ryan L.: Nothing to Disclose Westerlund, Erik: Consulting: Nuvasive (B); Research Support (Staff and/or materials): Seaspine (None, Research support); Scientific Advisory Board: Seaspine (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
21:48
March 25, 2021
Neuromonitoring Societies: Who Are They and What Are They Working On?
Who are the different neuromonitoring societies, what role(s) do they play in patient care, where are they focusing their efforts, and what opportunities are there for inter-society collaboration? In this episode, NASS IONM Section Co-Chair, Dr. Richard Vogel, is interviewed in his role as Past-President of the American Society of Neurophysiological Monitoring (ASNM). Disclosures: Doan, Adam: Other: Nuvasive Clinical Services  (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
14:15
February 23, 2021
Neuromonitoring: State of the Art in 2021 and Beyond
How many surgeries are monitored in the US each year? What portion are spine? Is use of IONM increasing or decreasing? What major trends do we see in the use of IONM in spine surgery, and what can we expect in the future? This episode hosted by Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan will answer all of these questions and more! Disclosures: Doan, Adam: Other: Nuvasive Clinical Services  (Salary); Private Investments: Veridical RCM (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Other: Nuvasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:33
February 4, 2021
Preventing Blood Loss in Spine Surgery with Tranexamic Acid
Featuring: Moderator Alex Michael, MD and Author James Reynolds, MD James Reynolds, MD, co-chair of NASS' Patient Safety Committee, discusses Preventing Blood Loss in Spine Surgery with Tranexamic Acid. Reducing blood loss during spine surgery is one of the many responsibilities of spine surgeons to keep patients safe. Dr. Reynolds addresses this and more in the latest episode discussing an article that recently appeared in SpineLine. Access the article here.  Disclosures: Michael, Alex P: Nothing to Disclose   Reynolds, James B.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
16:12
December 10, 2020
New Interventional Spine & Musculoskeletal Medicine Fellowships
Featuring: Moderator Renee Rosati, DO and Author David O'Brien, Jr., MD. NASS Treasurer David O'Brien, Jr., MD, discusses new Interventional Spine & Musculoskeletal Medicine Fellowships and the opportunities they will afford young physicians. Dr. O'Brien touches on NASS completing its inaugural ISMM fellowships with a 100% match, and more in this podcast with moderator Renee Rosati, DO. Access the SpineLine article here. Disclosures: O'Brien, David Reese: Nothing to Disclose   Rosati, Renee Michelle: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
24:36
October 27, 2020
Where Are We Headed with Endoscopic Spine Surgery
Featuring: Jin Sun Kim, MD and Michael Y. Wang, MD Disclosures: Kim, Jin Sun: Stock Ownership: Innovasive (1%); Consulting: Richard Wolf (Travel Expense Reimbursement), Elliquence (Travel Expense Reimbursement); Scientific Advisory Board: Innovasive (Nonfinancial); Grants: AOSpine (A). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:60
September 22, 2020
How to Minimize the Burden of Fusion with ERAS
Featuring: Michael Y. Wang, MD and Daniel K. Resnick, MD Disclosures: Resnick, Daniel: Scientific Advisory Board: NIDUS (None). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (1%), Medical Device Partners (1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:03
September 8, 2020
Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain
Moderator Douglas Pahl, MD, interviews authors Alex Mierke, MD, and Omar Ramos, MD, about their article titled, "Stem Cell Therapies in the Treatment of Disc-Related Low Back Pain." Drs. Mierke and Ramos discuss what is already known about stem cell therapies and what still may lie ahead in this ever-changing medical landscape. Access the article here. Disclosures: Mierke, Alex : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (
28:43
September 1, 2020
Considerations for Spinal Fusion Surgery in the Elderly: Osteoporosis, Sarcopenia & Frailty
Featuring: Joseph S. Butler, PhD, FRCS and Arjun S. Sebastian, MD Disclosures: Butler, Joseph S.: Nothing to Disclose (Sep 26, 2019).   Sebastian, Arjun S.: Nothing to Disclose (Feb 04, 2019) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:06
August 25, 2020
ALIF: Stand Alone and When to Back Up
Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B). Reddy, Deepak: Nothing to Disclose. Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:38
August 11, 2020
Use of Mesenchymal Cellular Bone Matrix in Complex Cervical Surgery
Featuring: Mark M. Mikhael, MD; Deepak Reddy, MD; Bradley Saitta, MD; Nick Shamie, MD Disclosures: Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B).  Reddy, Deepak: Nothing to Disclose.   Saitta, Bradley: Nothing to Disclose. Shamie, Nick: Royalties: Seaspine (B); Stock Ownership: SI Bone (100000 Shares, 1%), Vertiflex (200000 Shares, 1%); Consulting: Stryker (Financial, 0), Seaspine (Financial, 0), SI Bone (Financial, 0), Vertiflex (Financial, 0); Speaking and/or Teaching Arrangements: Medtronic (Financial, 0); Trips/Travel: Medtronic (Financial, 0); Board of Directors: Vertiflex (Financial, Medical Director); Scientific Advisory Board: SI Bone (Financial, Medical Advisory Board).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:60
July 28, 2020
Graft Selection for Interbody Fusion
Featuring: Zoher Ghogawala, MD; Han Jo Kim, MD; Khoi D. Than, MD Disclosures: Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Chair).   Kim, Han Jo: Board of Directors: AOSpine (B); Fellowship Support: AOSpine (D, Paid directly to institution/employer); Research Support (Staff and/or materials): CSRS (C, Outside 12-Month Requirement, Paid directly to institution/employer), ISSGF (C, Paid directly to institution/employer); Royalties: K2M (D), Zimmer Biomet (F).   Than, Khoi D.: Consulting: Bioventus (B), Medtronic (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:05
July 14, 2020
Spinal Masqueraders
Featuring: Evan K. Johnson, PT, DPT, OCS and Rick J. Placide, MD, PT Disclosures: Johnson, Evan K. : Nothing to Disclose.   Placide, Rick J. : Nothing to Disclose. Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:32
June 30, 2020
Navigating the Job Search for Spine Specialists
Featuring: Sandeep N. Gidvani, MD and Nickul Jain, MD Disclosures: Gidvani, Sandeep N.: Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Jain, Nickul: Consulting: Spineart (Future Compensation Expected); Research Support (Staff and/or materials): Globus Medical (Nonfinancial). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:28
June 16, 2020
How to Choose Between Posterior Interbody Fusions Versus Lateral Interbody Fusion
Featuring: Sandeep N. Gidvani, MD and Paul R. Gause, MD Disclosures: Gause, Paul R. : Speaking and/or Teaching Arrangements: Medtronic (C).  Gidvani, Sandeep N. : Consulting: Xenco Medical (B), SeaSpine (None), Spinal Balance (None), SI-BONE (None), NuVasive (None).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:07
June 2, 2020
Marketing Masquerading as Medical Information
Featuring: E. Kano Mayer, MD; Eeric Truumees, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark: Nothing to Disclose. Mayer, E. Kano: Stock Ownership: Infinite Orthopedics (1%); Private Investments: Lanai Health Solutions (30%); Speaking and/or Teaching Arrangements: North America Spine Society (B); Trips/Travel: NASS (B).   Truumees, Eeric: Trips/Travel: AAOS (Travel Expense Reimbursement); Board of Directors: Seton Family of Doctors (Salary); Other Office: AAOS Communications Cabinet (E, Travel Expense Reimbursement, Editor-in-Chief of AAOS Now); Research Support - Staff and/or Materials: Relievant (B, Paid directly to institution/employer), Medtronic (A), Vertex Pharma (A), Dova Pharmaceuticals (A), Pfizer (B, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer).   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:20
May 19, 2020
Stem Cells and Degenerative Disc Disease
Featuring: Zorica Buser, PhD and Mark Erwin, DC, PhD Disclosures: Buser, Zorica: Consulting: AOSpine (B, Outside 12-Month Requirement), Xenco Medical (B, Outside 12-Month Requirement); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): Next Science (F, Paid directly to institution/employer), SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AO Spine (Travel reimbursements for AO Spine Knowledge forum meetings and congresses).   Erwin, Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:02
May 5, 2020
Use of Bone Cement in Metastatic Spinal Disease and Beyond
Featuring: Matthew L. Goodwin, MD, PHD (Washington University), Dan Sciubba, MD (Johns Hopkins), and Joe Schwab, MD, MS (Harvard/Massachusetts General Hospital) Use of bone cement in the spine has been marred by early controversy, including debate over kyphoplasty/vertebroplasty and whether use of bone cement in spine surgery was safe or effective.  Now with recent publications reviewing almost 20 years of cement use in the spine, the data are relatively convincing that bone cement in spine surgery is not only useful, but also relatively safe.   In this podcast, these spine tumor surgeons from NASS' Section on Spine Oncology discuss the history of bone cement in the spine, the current use/indications for cement (e.g. metastatic spinal disease, osteoporosis), current techniques (e.g. through fenestrated pedicle screws), and discuss potential complications as well as practical tips for employing these techniques. Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy-Synthes (B), Globus (B), Medtronic (C), Nuvasive (B), Stryker (C). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
17:26
April 28, 2020
Identifying and Managing Physician Burnout in Today’s Health Care Environment
Did you know that physicians, as a group, have lower work-life satisfaction compared to the general population? The consequences of burnout are borne both by the individual physician and the health care system. The recognition of burnout as a serious individual and institutional challenge is leading to an increased need to design, implement, and evaluate systems that promote well-being. Moderator Richard L. Skolasky, Jr., Sc.D. interviews Todd Albert, MD and Eric Muehlbauer, MJ, CAE on this very important topic to assist the listener in ultimately being able to identify and strategize to mitigate risk factors in their own lives or in the organization that they represent. Disclosures: Albert, Todd J.: Board of Directors: American Orthopaedic Association (Nonfinancial, Treasurer-Elect), Hospital For Special Surgery (None, Surgeon-in-Chief Emeritus and Medical Director), Scoliosis Research Society (Nonfinancial, Past President); Consulting: Nuvasive (B); Other: JP Medical Publishers (B), Saunders/Mosby- Elsevier (B), Springer (A), Thieme Medical Publishers (B); Research Support (Staff and/or materials): PCORI (D); Royalties: DePuy Synthes Spine (F); Stock Ownership: ASIP (D), Augmedics (F), Biomerix (D, 42,253 Shares), Bonovo Orthopedics (D, 85,737 Shares), Crosstrees Medical  (D,  
24:08
April 14, 2020
Optimizing the High Risk Patient for Surgery and Burnout
Featuring: F. Todd Wetzel, MD; Carrie A. Diulus, MD; Mark Cuccuzella, MD Disclosures: Cuccuzella, Mark : Nothing to Disclose Diulus, Carrie A. : Trips/Travel: NASS (Travel Expense Reimbursement).   Wetzel, F. Todd : Stock Ownership: Relievant Medical (1%).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:10
March 31, 2020
Spinal Cord Mapping
Featuring: Lawrence G. Lenke, MD; Evan K. Johnson, PT, DPT, OCS; Neel Anand, MD Disclosures: Anand, Neel: Royalties: Medtronic (F), Nuvasive (B), Globus Medical (B), Elsevier (B); Stock Ownership: Globus (, unknown), Medtronics (, unknown); Private Investments: Paradigm Spine (, 1%, unknown), Bonovo Orthopaedics (, 1%, unknown), Pearl Diver (, 1%, unknown), Theracell (, 1%, unknown), GYS Tech (, 1%, unknown); Consulting: Spinal solutions (Financial, Stock options : Unknown ); Speaking and/or Teaching Arrangements: Medtronic (Financial, 42000); Trips/Travel: Medtronic (Financial, Included with consulting fees); Scientific Advisory Board: Globus Medical (Financial, 0). Johnson, Evan K. : Nothing to Disclose. Lenke, Lawrence G.: Consulting: DePuy Synthes (D, Outside 12-Month Requirement), K2M (D, Outside 12-Month Requirement), Medtronic (I, Outside 12-Month Requirement, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): Medtronic (I), Quality Medical Publishing  (A); Grants: Fox Family Foundation (A); Other: AOSpine (D, Paid directly to institution/employer), Broadwater (B), Scoliosis Research Society (B), The Spinal Research Foundation (Travel Expense Reimbursement); Research Support (Staff and/or materials): EOS Imaging (A), Setting Scoliosis Straight Foundation (A).     Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:59
March 24, 2020
Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?
Moderator Douglas Pahl, MD interviews Karthik Madhavan, MD about a SpineLine articled he helped author titled, "Augmented Reality, Virtual Reality and Artificial Intelligence: Are We There Yet?". Dr. Madhavan talks about the exciting developments with augmented reality and how there is still much to learn in the cutting-edge technology. This article first appeared in the January/February 2020 edition of SpineLine. Access the article here.  Disclosures: Madhavan, Karthik : Nothing to Disclose   Pahl, Douglas W.: Consulting: Stryker (C, Outside 12-Month Requirement, Paid directly to institution/employer); Other: Orthofix (A, Outside 12-Month Requirement); Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (
30:28
March 17, 2020
Epidural Abscess
Featuring: Joseph H. Schwab, MD; Andrew J. Schoenfeld, MD Disclosures: Schoenfeld, Andrew J.: Royalties: Wolters Kluwer, Springer (B); Consulting: ArborMetrix (C); Trips/Travel: JBJS (A); Other Office: Journal of Bone and Joint Surgery (C); Research Support - Staff and/or Materials: CMS (D, Paid directly to institution/employer); Grants: Department of Defense (D, Paid directly to institution/employer), OREF (D, Paid directly to institution/employer), NIH (F, Paid directly to institution/employer).   Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:38
March 10, 2020
Survival Prediction and Frailty Evaluation for Patients with Metastatic Tumors
Featuring: Joseph H Schwab, MD; Dan M Sciubba, MD; Ilya Laufer, MD Disclosures: Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 12-Month Requirement), Stryker Spine (B, Outside 12-Month Requirement).  Sciubba, Dan: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C).   Laufer, Ilya : Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), SpineWave (B).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:00
March 3, 2020
Value-Based Gap Analysis of Neuromonitoring
Featuring: F. Todd Wetzel, MD, John Ney, MD, Tara Stewart, PhD, DABNM Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Ney, John: Board of Directors: American Society for Neuromonitoring (None); Consulting: Ceribell (B), SpecialtyCare (B); Other Office: American Academy of Neurology, Medical Economics and Management Committee (Travel Expense Reimbursement); Speaking and/or Teaching Arrangements: SpecialtyCare (Travel Expense Reimbursement).  Stewart, Tara: Private Investments: IONM Life LLC (Future Compensation Expected, Paid directly to institution/employer) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:27
February 25, 2020
Lumbar Disc Replacement
Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Richard D. Guyer, MD: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Jack E. Zigler, MD: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:20
February 18, 2020
Psychologically Informed Practice
Featuring: F. Todd Wetzel, MD, Chris J. Main, MA, PhD, Gregory L. Whitcomb, DC Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Main, Chris J.: Consulting: Medrisk Inc International Scientific Advisory Board (B, Paid directly to institution/employer); Device or Biologic Distribution Group (Physician-Owned Distributorship): The Back Book (B).  Whitcomb, Gregory L.: Speaking and/or Teaching Arrangements: North American Spine Society (B); Trips/Travel: North American Spine Society (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
12:21
February 11, 2020
Cervical Disc Replacement
Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Guyer, Richard D.: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Zigler, Jack E.: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:30
February 4, 2020
Section on IONM: How to Optimize Neuromonitoring Episode 12
[12 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Are wakeups always prolonged with neuromonitoring under TIVA?” It’s a common complaint: we use TIVA for MEPs, but the patients take forever to wake up from anesthesia. To combat this problem, many surgeons elect to discontinue IONM earlier in the procedure. Did you know IONM has the technology to guide the anesthesia team through a faster wakeup in most cases? It requires communication and collaboration, but it’s easy to do. Here we review these techniques. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:34
December 10, 2019
Operating on Neurofibromas- What Have We Learned?
[3 of 3] In this newest episode from the Section on Spine Oncology , Drs. Schwab, Sciubba, and Goodwin discuss operating on neurofibromas.  Surgery on patients with neurofibromas can range from relatively straightforward (simple neurofibromas) to life-threatening (complex plexiform neurofibromas).  In patients with plexiform neurofibromas, particularly those near the spinal cord, care needs to be taken preoperatively, when considering surgical indications, as well as intra-operatively, where hemostasis can become challenging.   Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement),  Stryker Spine (B, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:35
December 3, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 11
[11 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Neuromonitoring lost their signals, now what?” Aside from checking wires and anesthesia, what else works? It turns out there is a lot one can do to restore signals. Here the Co-Chairs review these checks and interventions. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:25
November 26, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 10
[10 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss, "Diagnostic accuracy of IONM from the neurophysiologist’s perspective." They review the traditional diagnostic table (i.e., ± alert, ± deficit) and consider other factors like intervention, resolution of data, type of monitoring modality, etc. They also present an advanced diagnostic table that is inclusive of these factors. This has major implications for developing and interpreting research. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:34
November 19, 2019
Why Do You Need an X-Ray?
[2 of 3] In this podcast, Matthew Goodwin, MD, PhD, of Washington University Orthopaedics/Barnes-Jewish and the Washington University Spine Tumor Center and Section on Spine Oncology Chair, discusses the question often asked of spine surgeons by other services, "Why do you need an X-ray when we have a CT, MRI, etc?"   Hear him address this question with a few short case examples, five of the main reasons he requests radiographs, and how each is critical to providing optimal care to the patient. Disclosure: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:07
November 12, 2019
Injectable Biologic Therapies for Intervertebral Disc
Featuring: Zorica Buser, PhD, Mark Erwin, DC, PhD Disclosures: Buser, Zorica: Consulting: AOSpine (B), Xenco Medical (B); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement). Erwin, William Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:27
November 5, 2019
Medical Management of Spinal Cord Injury
Featuring: Christina L. Goldstein, MD, FRCSC, Scott D. Daffner, MD, Gregory D. Schroeder, MD Disclosures: Daffner, Scott D.: Consulting: Bioventus (B); Fellowship Support: AO Spine (E, Paid directly to institution/employer),  Medtronic (D, Outside 12-Month Requirement, Paid directly to institution/employer); Grants: AO Foundation (F, Outside 12-Month Requirement, Paid directly to institution/employer),  CSRS (F, Outside 12-Month Requirement, Paid directly to institution/employer); Other Office: CSRS (Research Committee),  LSRS (Program Committee),  NASS (Section on Biologics & Basic Research),  NASS (Membership Committee); Research Support (Staff and/or materials): Bioventus (C, Paid directly to institution/employer),  Pfizer (D, Paid directly to institution/employer),  Spinal Kinetics (B, Paid directly to institution/employer); Stock Ownership (including options, warrants): Amgen (
10:18
October 15, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 9
[9 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Is it really an alert? Whence the criteria?” The criteria for calling an alert in IONM have evolved over the years and many people don’t know what the latest research says. This causes a lot of false positives (and some false negatives). We review what really constitutes an alert and how you can use IONM to improve accuracy. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
12:44
October 8, 2019
Special Considerations When Treating Athletes with Low Back Pain
Featuring: Evan K. Johnson, PT, DPT, OCS, Rick J. Placide, MD, PT Disclosures: Johnson, Evan K.: Nothing to Disclose   Placide, Rick J.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:40
October 1, 2019
An Introduction to Predictive Models for Spinal Metastases
[1 of 3] Hosted by Joseph H. Schwab, MD and Matthew L. Goodwin, MD, PhD, this episode by the Section on Spine Oncology discusses the question, "Why do we want to be concerned about systemic disease and predict survival?" The hosts review the concept of predictive modeling for spinal metastases and include discussion on NOMs and SINs criteria, reviewing the strengths and weaknesses of each and finishing up the talk by using the NOMs criteria to discuss systemic disease. Disclosures: Goodwin, Matthew L.: Consulting: Augmedics (A); Fellowship Support: AO Spine  (Salary, Fellowship Support), NREF (Salary, Fellowship Support); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement),  Stryker Spine (B, Outside 12-Month Requirement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
15:37
September 17, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 8
[8 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What can you do to improve accuracy of pedicle screw stimulation?” Pedicle screw stimulation was developed and tested under very specific methods, but very few people follow these methods, and this reduces the accuracy. We return to the basics and make recommendations that help even the most seasoned practitioner. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
14:60
September 10, 2019
Management of Degenerative Cervical Myelopathy
Featuring: Michael G. Fehlings, MD, PhD, FRCSC, Paul M. Arnold, MD Disclosures: Arnold, Paul M.: Board of Directors: AANS/CNS Joint Section on Neurotrauma (Nonfinancial), CSRS (Nonfinancial), LSRS (Nonfinancial), SpineEx (1%); Consulting: Asterias (A, Outside 12-Month Requirement), Cerapedics (C), Medtronic (B), Spine Wave (B); Research Support (Staff and/or materials): Evoke Medical, LLC (40%, Paid directly to institution/employer). Fehlings, Michael G.: Consulting: Fortuna Fix (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:41
September 3, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 7
[7 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Are there any real contraindications to MEPs?” This episode, the Co-Chairs cut through the common myths associated with MEP contraindications: there are no absolute contraindications and all of the relative contraindications have actually been shown to be quite safe.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:04
August 27, 2019
Robotics in Spine Surgery
Featuring: Michael Y. Wang, MD, Michael P. Steinmetz, MD Disclosures: Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
07:55
August 20, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 6
[6 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “How can you use neuromonitoring to guide and optimize positioning for spine surgery?” The patient is finally in position and neuromonitoring can’t get baselines. What do you do? If you elect to intervene, it’s a long process to retest baselines in a neutral position. Then, you have to reposition all over again. Here the Co-Chairs present a fast, efficient, systematic way to position a patient for any spine surgery to ensure the spinal cord is stable, and all peripheral nerves and plexi are not compressed or stretched. Also, they talk about positioning possibilities for all patients; not just those with unstable spines. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:39
August 13, 2019
Endoscopic Spine Surgery and its Future
Featuring: Peter Witt, MD, Michael Y. Wang, MD Disclosures: Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
08:49
August 6, 2019
Cervical Disc Arthroplasty - Surgeon Reluctance To Adopt The Technology
Featuring: Mark M. Mikhael, MD, Christopher F. Wolf, MD, Nick Shamie, MD, Lisa A. Ferrara, PhD Disclosures: Ferrara, Lisa A.: Consulting: OrthoKinetic Technologies (Salary, Paid directly to institution/employer); Scientific Advisory Board: 4Web (
10:41
July 23, 2019
Treatment Options for L4-5 Mobile Degenerative Lumbar Spondylolisthesis: Open or MI
Featuring: Nathaniel P. Brooks, MD, Khoi D. Than, MD, Michael P. Steinmetz, MD Disclosures: Brooks, Nathaniel P.: Other: NASS (Minimally Invasive Procedure Section Chair). Than, Khoi Duc: Consulting: Bioventus (B),  Medtronic (A). Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:41
July 9, 2019
Avoiding Unnecessary Lumbar Surgery While Improving Surgical Outcomes
Featuring: Ronald G. Donelson, MD, MS, Ryan A. Tauzell, PT, MA, MDT, F. Todd Wetzel, MD Disclosures: Donelson, Ronald G.: Scientific Advisory Board: Chord Health Inc. (A); Stock Ownership: Chord Health Inc (A, 4%). Tauzell, Ryan A.: Other: North American Spine Socity (Travel Expense Reimbursement). Wetzel, F. Todd: Stock Ownership: Relievant Medical (
08:08
June 25, 2019
A Biopsychosocial Approach in the Management of Chronic Low Back Pain
Moderator Chad Patton, MD, interviews SpineLine authors Sarah C. Rispinto, PhD and Kush Goyal, MD, to discuss their article, “A Biopsychosocial Approach in the Management of Chronic Low Back Pain in a Large Hospital System: Program Feasibility and Initial Outcomes.”  The article first appeared in the July/August 2018 edition of SpineLine.  Access the article here.  Disclosures: Goyal, Kush K.: Nothing to Disclose Patton, Chad M.: Speaking and/or Teaching Arrangements: Baxter (B), Medtronic (B); Stock Ownership: Physiciancy Medical Scribes (
31:12
June 18, 2019
Spinal Diagnostics: The Benefit of Identifying Patterns of Pain Response
Featuring: Ronald G. Donelson, MD, MS, Ryan Tauzell, PT, MA, MDT, F. Todd Wetzel, MD Disclosures: Donelson, Ronald G.: Scientific Advisory Board: Chord Health Inc. (A); Stock Ownership: Chord Health Inc (A, 4%). Tauzell, Ryan A.: Other: North American Spine Socity (Travel Expense Reimbursement). Wetzel, F. Todd: Stock Ownership: Relievant Medical (
08:22
June 11, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 5
[5 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Does use of IONM necessarily add time to your surgery?”  The short answer is yes, but a closer look will show that it is negligible if the IONM team can work efficiently and in collaboration with the rest of the patient care team in the operating room. We’ll discuss how setup can be optimized, and how baselines can be acquired in as little as 30 seconds. We’ll also show how improved communication can reduce false positives and keep the surgery moving smoothly.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
06:50
June 4, 2019
Definitive Radiation for Oligo Metastatic Disease
Featuring: Joseph H. Schwab, MD, Ilya Laufer, MD, Daniel M. Sciubba, MD Disclosures: Laufer, Ilya: Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), SpineWave (B). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement),  Stryker Spine (B, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:57
May 28, 2019
Trends in Decision Making for Biologics
Featuring: Joseph S. Butler, PhD, FRCS, Gregory D. Schroeder, MD Disclosures: Butler, Joseph S.: Nothing to Disclose   Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:50
May 14, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 4
[4 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, "What are the anesthetic recommendations for neuromonitoring in various spine surgeries and why?”  The Co-Chairs discuss when and why they recommend total intravenous anesthesia (TIVA) vs 0.5 MAC. Is Ketamine really beneficial to MEPs? Why is Precedex contraindicated for MEPs? What train-of-four ratio is recommended for monitoring, when and why? They’ll answer all these questions and more. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:37
May 7, 2019
Separation Surgery Along with Stereotactic Radio Surgery for Metastatic Disease
Featuring: Joseph H. Schwab, MD, Ilya Laufer, MD, Daniel M. Sciubba, MD Disclosures:  Laufer, Ilya: Consulting: BrainLab (A), DePuy Synthes (B), Globus (B), Medtronic (C), SpineWave (B). Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (None); Speaking and/or Teaching Arrangements: AO Spine (Travel Expense Reimbursement, Outside 12-Month Requirement),  Stryker Spine (B, Outside 12-Month Requirement). Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Globus (B), Medtronic (C), NuVasive (B), Stryker (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
05:29
April 30, 2019
Ideal Treatment For a Symptomatic Grade I/II L4-5 Spondylolisthesis
Featuring: Paul R. Gause, MD, Sandeep N. Gidvani, MD  Disclosures: Gause, Paul R.: Speaking and/or Teaching Arrangements: Medtronic (C). Gidvani, Sandeep N.: Consulting: Xenco Medical  (B), Seaspine  (None), Spinal Balance  (None), SI Bone (None), Nuvasive (None). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:58
April 16, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 3
[3 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Why does IONM need access to my patients and their charts before and after surgery?”  It’s not uncommon for hospitals/surgeons to prohibit the IONM team from interfacing with the patient before surgery. In addition to needing informed consent, the team needs to assess the patient’s neuro status and history to interpret the IONM data. Imaging/charts help to develop an appropriate IONM plan. Facesheets are essential to reimbursement. When the IONM team is unable to access patient records, they are monitoring in the dark (and for free). Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:52
April 4, 2019
Minimally Invasive Spine Deformity Surgery
Featuring: Michael Y. Wang, MD, Michael P. Steinmetz, MD  Disclosures: Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
08:34
April 2, 2019
How Does Psychologically Informed Practice Influence Outcome?
Featuring: Gregory L. Whitcomb, DC, F. Todd Wetzel, MD  Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (
08:49
March 19, 2019
Drowning in Denials: The Insurance Denial & Appeal Process
Diana Wiseman, MD (Public Affairs Committee Member) and Donna Lahey, RNFA, CNOR (Author) discuss the Socioeconomics & Politics article, "Drowning in Denials: The Insurance Denial & Appeal Process," which was published in the May/June 2018 issue of NASS' SpineLine magazine. Access the article here. Disclosures: Lahey, Donna M.: Speaking and/or Teaching Arrangements: NASS (B, Paid directly to institution/employer); Trips/Travel: NASS (Travel Expense Reimbursement, Paid directly to institution/employer). Wiseman, Diana Barrett: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
40:31
March 15, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 2
[2 of 12] Hear from Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, "Neuromonitoring in spine surgery, can't anyone cover the case?" Did you know IONM is learned through on-the-job training, licensure does not exist, and certifications are not required for the technologist in your OR? After initial training, technologists can monitor very basic cases (e.g., PLIF), but they should spend years in training to learn more complex procedures (deformity, tumors). If a surgery isn’t booked accurately, the surgeon might get a very junior person assigned to a very complex case. Here we inform the listener of common practices around determining “competency” for performing IONM in spine surgery.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
07:55
March 6, 2019
What Are The Real Criteria for a Neuromonitoring Alert In Spine Surgery?
Featuring: Richard Vogel, PhD, DABNM, Adam Doan, DC, DABNM, Anthony K. Sestokas, PhD, DABNM  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Sestokas, Anthony K.: Other Office: Journal Of Clinical Monitoring And Computing (Editorial board), NASS Section On Intraoperative Neuromonitoring (Member of Section on IONM), SpecialtyCare (F, Chief Clinical Officer - IONM; Salary); Stock Ownership: KSPC Holdings (C) Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:34
March 5, 2019
Benefits of an Interdisciplinary Spine Practice
Featuring: Eeric Truumees, MD, E. Kano Mayer, MD, John Stokes, MD, Enrique B. Pena, MD  Disclosures: Mayer, E. Kano A.: Stock Ownership: Infinite Orthopedics (
11:26
February 19, 2019
Spine Surgery In The Elderly
Featuring: Jack Jallo, MD, PhD, FACS, Srinivas K. Prasad, MD, Joshua E. Heller, MD, MBA  Disclosures: Heller, Joshua E.: Consulting: Nuvasive (D),  Providence Medical Technology (D),  SI Bone (C). Jallo, Jack: Nothing to Disclose   Prasad, Srinivas K.: Royalties: Stryker Spine (D); Consulting: Stryker Spine (D), Globus Medical (B), SpineWave (B), Depuy-Synthes (C); Speaking and/or Teaching Arrangements: Stryker Spine (D), Depuy-Synthes (B); Board of Directors: AKOS Health Systems (Nonfinancial, Board Member, Investor); Fellowship Support: AO Spine (E, Paid directly to institution/employer), NREF (E, Paid directly to institution/employer). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:21
February 5, 2019
Lumbar Spine Fusion: The Patient's Perspective
Dr. Vivek Mohan discusses Lumbar Spine Fusion with one of his former patients. Disclosure: Mohan, Vivek: Consulting: AIM Specialty Health (B), Baxter (B), Seaspine (C); Speaking and/or Teaching Arrangements: Providence Medical (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
23:24
February 4, 2019
Epidural Abscess
Featuring: Christopher M. Bono, MD, F. Todd Wetzel, MD, William C. Watters, MD, MS Disclosures: Bono, Christopher M.: Royalties: Wolters Kluwer (A), Elsevier (B); Consulting: United Health Care (B); Other Office: The Spine Journal (D); Fellowship Support: OMEGA (D, Paid directly to institution/employer). Watters, William C.: Board of Directors: American Board Of Spine Surgery (None); Consulting: Interqual (B), Intrinsic Therapeutics (A), MCG Health (None). Wetzel, F. Todd: Stock Ownership: Relievant Medical (
07:24
January 22, 2019
Section on IONM: How to Optimize Neuromonitoring Episode 1
[1 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What information is critical to communicate to the IONM team and how far in advance of surgery?” It’s not uncommon for the IONM team to learn the details of the surgical procedure after incision, as it unfolds. This poses a number of problems. The IONM team needs to know detailed surgical plan, diagnosis and patient insurance information at least 48-hours in advance for non-emergent surgery. This will make IONM less likely to fail because the IONM team can make sure the correct equipment/electrodes/people are in the room, and the correct tests are being run with optimized anesthesia. This will also limit common issues with insurance.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
05:01
January 15, 2019
How to Manage Acute Pain for Patients
Faisel Zaman, MD, Chair of the Patient Education Committee, discusses acute back pain. Disclosure: Zaman, Faisel M.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:24
December 13, 2018
Degenerative Disc Disease for Patients
Faisel Zaman, MD, Chair of the Patient Education Committee, discusses causes and treatments for degenerative disc disease. Disclosure: Zaman, Faisel M.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
13:34
October 8, 2018
Physician and Hospital Reputation Management
Douglas Pahl, MD (Public Affairs Committee Chair), William Sullivan, MD (SpineLine Medical Editor) and Andrew Pugely, MD (Author) discuss the Value in Spine Care article, "Physician and Hospital Reputation Management: How to Navigate the Quagmire of Public Quality Rankings, Patient Satisfaction and Online Review," which was published in the March/April 2018 issue of NASS' SpineLine magazine. Access the article here.  Disclosures: Pahl, Douglas W.: Stock Ownership: Nanovis (14,837 Shares, Paid directly to institution/employer), Trainer Rx (
56:22
September 17, 2018
Invited Review- "Risk Stratification and the Future of Spine Surgery"
Chad Patton, MD (Public Affairs Committee Chair), William Sullivan, MD (SpineLine Medical Editor) and Emily Miller, MD (Review Author) discuss the Invited Review article on "Risk Stratification and the Future of Spine Surgery," which was published in the January/February 2018 issue of NASS' SpineLine magazine. Access the article here. Disclosures: Patton, Chad M.: Speaking and/or Teaching Arrangements: Baxter (B), Medtronic (B); Stock Ownership: Physiciancy Medical Scribes (
36:31
September 10, 2018
Women's Issues in Spine Care
Saralyn Mark, MD (iGIANT, Yale University, Georgetown University), Kimberly J. Templeton, MD (University of Kansas) and Gregory Whitcomb, DC (Medical College of Wisconsin) discuss women’s issues in spine care.   Disclosures: Mark, Saralyn: Nothing to Disclose Templeton, Kimberly J.: Nothing to Disclose  Whitcomb, Gregory L.: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
09:03
September 10, 2018
Will We Still Be Doing PSO's (Pedicle Subtraction Osteotomy) in 10 Years?
Sigurd Berven, MD (University of California San Francisco) and Michael Y. Wang, MD, FACS (The University of Miami) discuss the practice of and future of pedicle subtraction osteotomies. Disclosures: Berven, Sigurd H.: Consulting: Innovasis (B), Medicrea (C), Medtronic (C); Fellowship Support: Globus Medical (D); Grants: AO Spine (E, Paid directly to institution/employer), Globus (D, Paid directly to institution/employer); Private Investments: Green Sun Medical (50,000 Shares); Royalties: Stryker (F); Scientific Advisory Board: Globus Medical (Stock options); Speaking and/or Teaching Arrangements: Medtronic (B), Stryker Spine (B); Stock Ownership: Globus Medical (25,000 Shares), Providence Medical (2,500 Shares); Trips/Travel: Scoliosis Research Society (Travel Expense Reimbursement, Paid directly to institution/employer). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
11:52
September 10, 2018
Surgical Management of Degenerative Spondylolisthesis
Daniel Resnick, MS, MD (Madison, WI), Eeric Truumees, MD (Austin, TX), Zoher Ghogawala, MD (Boston, MA) and Jeffrey Wang, MD (Los Angeles, CA) discuss the trends in treatment of degenerative spondylolisthesis. Disclosures: Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Nonfinancial, Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Nonfinancial, Chair). Resnick, Daniel K.: Scientific Advisory Board: NIDUS (None). Truumees, Eeric: Board of Directors: Seton Family of Doctors (No additional pay, part of base compensation); Other Office: AAOS Communications Cabinet (E); Research Support (Staff and/or materials): Dova Pharmaceuticals (A, Paid directly to institution/employer), Medtronic (C, Paid directly to institution/employer), Pfizer (E, Paid directly to institution/employer), Relievant (F, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer), Vertex Pharma (D, Study cancelled, Outside 12-Month Requirement, Paid directly to institution/employer); Trips/Travel: AAOS (Travel Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:52
September 10, 2018
Quality of Life Surgery in Metastatic Disease of the Spine
Chris Steyn, MD (McMaster University) and Christina Goldstein MD, FRCSC (University of Missouri) discuss quality of life for patients with metastatic disease of the spine. Disclosures: Steyn, Chris : Nothing to Disclose   Goldstein, Christina L.: Consulting: SpineSource (B); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (B, Paid directly to institution/employer), DePuy Synthes Spine (A); Other Office: North American Spine Society (Nonfinancial, Coverage Committee, Section on Biologics and Basic Research); Grants: University of Missouri Coulter Translational Partnership (C, Paid directly to institution/employer), Musculoskeletal Transplant Foundation (E). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:51
September 10, 2018
Proximal Junctional Kyphosis
Sigurd Berven, MD (University of California San Francisco) and Michael Y. Wang, MD, FACS (The University of Miami) review proximal junctional kyphosis. Disclosures: Berven, Sigurd H.: Consulting: Innovasis (B), Medicrea (C), Medtronic (C); Fellowship Support: Globus Medical (D); Grants: AO Spine (E, Paid directly to institution/employer), Globus (D, Paid directly to institution/employer); Private Investments: Green Sun Medical (50,000 Shares); Royalties: Stryker (F); Scientific Advisory Board: Globus Medical (Stock options); Speaking and/or Teaching Arrangements: Medtronic (B), Stryker Spine (B); Stock Ownership: Globus Medical (25,000 Shares), Providence Medical (2,500 Shares); Trips/Travel: Scoliosis Research Society (Travel Expense Reimbursement, Paid directly to institution/employer). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
08:53
September 10, 2018
Physical Therapy: Pre- or Post-Planned Spine Surgery
Thomas E. Dreisinger, PhD, FACSM, Ezequiel D. Gherscovici, PT and Evan K. Johnson, PT, DPT, OCS discuss physical therapy before and after spine surgery. Disclosures: Dreisinger, Ted E.: Nothing to Disclose Gherscovici, Ezequiel D.: Speaking and/or Teaching Arrangements: The McKenzie institute (Financial, USD $4,000). Johnson, Evan K.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
10:01
September 10, 2018
Management and Complications of Spine Instrumentation in Patients with Osteoporosis
A. Jay Khanna, MD (Johns Hopkins University) and Charles A. Reitman, MD (The Medical University of South Carolina Charleston) discuss management and complication of spine instrumentations in the treatment of osteoporosis. Disclosures: Khanna, A. Jay: Consulting: Orthofix Spine (C); Device or Biologic Distribution Group (Physician-Owned Distributorship): Ortho Development (B), Thieme Medical Publishers (B); Grants: Siemens Healthcare (B, Paid directly to institution/employer); Other Office: Johns Hopkins Center for Bioengineering, Innovation and Design (Advisory Board, Paid directly to institution/employer); Private Investments (including venture capital, start-ups): Avitus Orthopaedics (9%), Cortical Concepts (16%), New Era Orthopaedics (15%); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (A). Reitman, Charles A.: Board of Directors: NASS (Travel Expense Reimbursement); Other: NASS (Nonfinancial); Scientific Advisory Board: Clinical Orthopaedics And Related Research (B, Paid directly to institution/employer). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:56
September 10, 2018
Is Surgery for Axial Back Pain Still an Option?
Scott L. Blumenthal, MD (Texas Back Institute), Rolando Garcia Jr., MD, MPH (Miami, FL) and Gregory D. Schroeder, MD (The Rothman Institute) answer the question of whether surgery is an option for axial back pain. Disclosures: Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (
12:38
September 10, 2018
The Impact of Gender-Sex on Innovation and Novel Technologies
Saralyn Mark, MD (iGIANT, Yale University, Georgetown University) and Gregory Whitcomb, DC (Medical College of Wisconsin) discuss the impact of gender on new technology in spine care. Disclosures: Mark, Saralyn: Nothing to Disclose Whitcomb, Gregory L.: Nothing to Disclose   Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
05:38
September 10, 2018
Cervical Myelopathy Anterior vs. Posterior
Scott L. Blumenthal, MD, Rolando Garcia Jr., MD, MPH and Gregory D. Schroeder, MD debate anterior versus posterior cervical myelopathy. Disclosures: Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (
10:00
September 10, 2018
Cellular-Based Allografts
Brandon Lawrence, MD (University of Utah) and Harvey E. Smith, MD (University of Pennsylvania Department of Orthopaedic Surgery) discuss cellular-based allografts. Disclosures: Lawrence, Brandon Douglas: Board of Directors: AO Spine North America (Nonfinancial, Paid directly to institution/employer),  Cervical Spine Research Society (Nonfinancial, Paid directly to institution/employer); Fellowship Support: AO Spine North America (E, Paid directly to institution/employer); Trips/Travel: AO Spine North America (B, Paid directly to institution/employer). Smith, Harvey E.: Stock Ownership: Johnson And Johnson (200 Shares, 100.00%); Trips/Travel: Biedermann Medtech (A), Depuy/Johnson&Johnson (A), Nuvasive (Nonfinancial), Stryker (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
06:17
September 10, 2018
Who Is the Ideal Patient for SI Fusion? Who Is Not?
Matthew Smuck, MD (Stanford University) and Joshua E. Heller, MD (Thomas Jefferson University) discuss patient selection for sacroiliac dysfunction. Disclosure: Heller, Joshua E.: Consulting: Nuvasive (D),  Providence Medical Technology (D),  SI Bone (C). Smuck, Matthew: Board of Directors: Spine Intervention Society (None); Consulting: Consultant & expert witness - State Farm (F), Spine Biopharma (Future Compensation Expected); Grants: Relievant Medsystems (F, Paid directly to institution/employer), ReWalk (E, Paid directly to institution/employer); Private Investments: Vivametrica (15.00%); Scientific Advisory Board: BlueJay Mobile-Health (Stock options), NuSpine (Stock options); Stock Ownership: BlueJay Mobile-Health (
11:40
September 10, 2018
What is the Best Operation for My Patient with Cervical Myelopathy?
Zoher Ghogawala, MD, FACS (Lahey Clinic and Tufts University School of Medicine) and Srinivas K. Prasad, MD (Thomas Jefferson University) address decision making process regarding cervical myelopathy. Disclosures: Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Nonfinancial, Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Nonfinancial, Chair). Prasad, Srinivas K.: Royalties: Stryker Spine (D); Consulting: Stryker Spine (D), Globus Medical (B), SpineWave (B), Depuy-Synthes (C); Speaking and/or Teaching Arrangements: Stryker Spine (D), Depuy-Synthes (B); Board of Directors: AKOS Health Systems (Nonfinancial, Board Member, Investor); Fellowship Support: AO Spine (E, Paid directly to institution/employer), NREF (E, Paid directly to institution/employer). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
11:30
September 10, 2018
Laminoplasty vs. ACDF
Jeffrey C. Wang, MD (University of Southern California Spine Center), Raymond J. Hah, MD (Keck School of Medicine at University of Southern California), John C. France, MD (West Virginia University) and Sheeraz A. Qureshi, MD, MBA (Mount Sinai School of Medicine) discuss laminoplasty vs. anterior cervical fusion. Disclosures: France, John C.: Nothing to Disclose   Hah, Raymond J: Consulting: Nuvasive (D). Qureshi, Sheeraz A: Board of Directors: Minimally Invasive Spine Surgery Group (Nonfinancial); Consulting: Globus (B),  K2M (D),  Paradigm Spine (C),  RTI (Nonfinancial),  Stryker Spine (D); Other: Healthgrades (B); Other Office: AAOS (Nonfinancial, Evaluations Committee member),  CSRS (Nonfinancial, Program Committee),  CSRS (Nonfinancial, Survey Committee),  NASS (Nonfinancial, MIS Committee),  NASS (Nonfinancial, Value Committee); Private Investments (including venture capital, start-ups): Avaz Surgical (2%),  Vital 5 (2%); Scientific Advisory Board: Onpoint Surgical, Inc. (Nonfinancial),  Zimmer (Nonfinancial); Speaking and/or Teaching Arrangements: Globus (Nonfinancial),  Medtronic (Nonfinancial),  Stryker (Nonfinancial). Wang, Jeffrey C.: Board of Directors: AOFoundation (C), Cervical Spine Research Society (Travel Expenses), North American Spine Society (Travel Expenses); Fellowship Support: AO Foundation (E, Paid directly to institution/employer); Private Investments: Bone Biologics (
10:11
September 10, 2018
Is Surgery Indicated for a Type II Odontoid Fracture?
Alexander R. Vaccaro, MD, PhD (Thomas Jefferson University), Rick C. Sasso, MD (Indiana Spine Group and Indiana University School of Medicine), Carlo Bellabarba, MD (University of Washington and Harborview Medical Center) and Christopher K. Kepler, MD, MBA (Thomas Jefferson University) discuss type II odontoid fractures. Disclosures: Bellabarba, Carlo: Nothing to Disclose   Kepler, Christopher K.: Grants: NIH (I, Paid directly to institution/employer); Other Office: Clinical Spine Surgery (Nonfinancial); Research Support (Staff and/or materials): CSRS (D, Paid directly to institution/employer), RTI (C, Paid directly to institution/employer); Royalties: Inion (None). Sasso, Rick C.: Board of Directors: Cervical Spine Research Society (None); Consulting: NuVasive (C); Research Support (Staff and/or materials): Cerapedics (E, Paid directly to institution/employer), Medtronic (B, Paid directly to institution/employer), Smith and Nephew (D, Paid directly to institution/employer); Royalties: Medtronic (I). Vaccaro, Alexander R.: Board of Directors: AO Spine (Knowledge Forum Director),  Flagship Surgical (None),  Innovative Surgical Design (None),  Parvizi Surgical Innovation (Nonfinancial),  Prime Surgeons (Nonfinancial),  Progressive Spinal Technologies (Nonfinancial),  Spine Therapy Network Inc (Nonfinancial); Consulting: Atlas Spine (B),  Depuy (None),  Gerson Lehrman Group (None),  Globus (C),  Guidepoint Global (B),  Innovative Surgical Design (None),  Medtronics (B),  Nuvasive (None),  Orthobullets (None),  Spine Wave (B),  Stout Medical (None),  Stryker Spine (F); Other: Clinical Spine Surgery (Editor in Chief); Royalties: Elsevier (B),  Globus (F),  JayPee Books (A),  Medtronic (E),  Stryker Spine (F),  Taylor Francis (A),  Thieme (B); Stock Ownership (including options, warrants): Advanced Spinal Intellectual Properties (30%),  Avaz Surgical (
10:36
September 10, 2018
How to Handle Degenerative Scoliosis
Charles A. Reitman, MD (Medical University of South Carolina Department of Orthopaedics), Michael Y. Wang, MD (University of Miami Hospital) and Michael D. Daubs, MD (University of Nevada Las Vegas School of Medicine) discuss degenerative scoliosis. Disclosures: Reitman, Charles A.: Board of Directors: NASS (Travel Expense Reimbursement); Other: NASS (Nonfinancial); Scientific Advisory Board: Clinical Orthopaedics And Related Research (B, Paid directly to institution/employer). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (
12:49
September 10, 2018
Complications
Norman B. Chutkan, MD, FACS (University of Arizona College of Medicine and The CORE Institute), Michael J. Vives, MD (Rutgers University, New Jersey Medical School) and F. Todd Wetzel, MD (Temple University School of Medicine) address complications. Disclosures: Chutkan, Norman B.: Royalties: Globus Medical (D); Speaking and/or Teaching Arrangements: AO North America (Nonfinancial, Travel Expense Reimbursement); Board of Directors: NASS (Travel Expense Reimbursement). Vives, Michael J.: Private Investments: Accelalox (
10:43
September 10, 2018
3D Printing
Alan Dang, MD (University of California San Francisco) and Wellington K. Hsu, MD (Northwestern University Feinberg School of Medicine) address 3D printing. Disclosures:  Dang, Alan: Stock Ownership: PrinterPrezz, Inc. (2%); Consulting: Johnson & Johnson (F, Paid directly to institution/employer); Speaking and/or Teaching Arrangements: Medtronic (None); Other Office: PrinterPrezz, Inc (Co-founder, Chief Medical Officer); Other: Ratcliffe/Ge/Dang (Co-inventor). Hsu, Wellington K.: Royalties: Stryker (F); Consulting: Stryker (F), AlloSource (B), Wright Medical (B), Medtronic (B), Mirus (B); Speaking and/or Teaching Arrangements: AONA (A); Trips/Travel: Stryker (B), Medtronic (B), Micro Medicine (A); Board of Directors: Lumbar Spine Research Society (None), American Academy of Orthopaedic Surgeons (None), North American Spine Society (None), Cervical Spine Research Society (None); Scientific Advisory Board: Bioventus (None); Grants: Medtronic (E, Paid directly to institution/employer). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
08:21
September 10, 2018